Sarifakioglu E, Seçkin D, Demirbilek M, Can F
Department of Dermatology, Başkent University Faculty of Medicine, Ankara, Turkey.
Clin Exp Dermatol. 2007 Nov;32(6):675-9. doi: 10.1111/j.1365-2230.2007.02480.x. Epub 2007 Aug 22.
Dermatophytes are the major responsible organisms in onychomycosis. Although recent antifungal agents have high success rates in treating this condition, lack of clinical response may occur in 20%. Antifungal drug resistance may be one of the causes of treatment failure. The need for in vitro antifungal drug resistance in daily practice is still under discussion.
We aimed to determine the in vitro susceptibility patterns of dermatophytes causing onychomycosis, against the traditionally available systemic antifungal agents terbinafine, itraconazole and fluconazole.
In total, 100 otherwise healthy patients with suspected onychomycosis were included. Nail clippings were cultured on Sabouraud dexrose agar, mycobiotic agar and dermatophyte test medium. Antifungal susceptibility tests were carried out, mainly following The National Committee for Clinical and Laboratory Standards (M38-P) protocol standard for filamentous fungi. Different concentrations of terbinafine (0.008-8 microg/mL), itraconazole (0.015-16 microg/mL) and fluconazole (0.06-64 microg/mL) were tested. Minimum inhibitory concentration end-point determination was chosen as 100% growth inhibition for terbinafine and 80% for azoles.
Of the 100 nail samples, 43% grew dermatophytes. The main causative organism was Trichophyton rubrum (91%) followed by Trichophyton mentagrophytes (9%). Terbinafine had the lowest minimum inhibitory concentration (0.008 microg/mL) followed by itraconazole. Fluconazole showed the greatest variation in minimum inhibitory concentration (0.03-2 microg/mL) and had different susceptibility patterns for the two species.
Of the three antifungals tested, terbinafine had the most potent in vitro antifungal activity against dermatophytes. Antifungal susceptibility tests would be useful to screen antifungal-resistant dermatophyte strains.
皮肤癣菌是甲癣的主要致病微生物。尽管近期的抗真菌药物在治疗该病方面成功率较高,但仍有20%的患者可能出现临床治疗反应不佳的情况。抗真菌药物耐药性可能是治疗失败的原因之一。日常实践中对体外抗真菌药物耐药性检测的必要性仍存在争议。
我们旨在确定引起甲癣的皮肤癣菌对传统的全身性抗真菌药物特比萘芬、伊曲康唑和氟康唑的体外药敏模式。
共纳入100例疑似甲癣的健康患者。将指甲剪屑接种于沙氏葡萄糖琼脂、真菌琼脂和皮肤癣菌测试培养基上。主要按照美国国家临床和实验室标准委员会(M38-P)丝状真菌协议标准进行抗真菌药敏试验。测试了不同浓度的特比萘芬(0.008 - 8微克/毫升)、伊曲康唑(0.015 - 16微克/毫升)和氟康唑(0.06 - 64微克/毫升)。最低抑菌浓度终点判定标准为特比萘芬为100%生长抑制,唑类为80%生长抑制。
100份指甲样本中,43%培养出皮肤癣菌。主要致病微生物为红色毛癣菌(91%),其次是须癣毛癣菌(9%)。特比萘芬的最低抑菌浓度最低(0.008微克/毫升),其次是伊曲康唑。氟康唑的最低抑菌浓度变化最大(0.03 - 2微克/毫升),且对两种菌的药敏模式不同。
在所测试的三种抗真菌药物中,特比萘芬对皮肤癣菌具有最强的体外抗真菌活性。抗真菌药敏试验有助于筛选耐抗真菌药物的皮肤癣菌菌株。